A new set‐up of vanishing antibodies: A biennial follow‐up of five different clients' humoral responses against SARS‐CoV‐2 after systemic vaccination in an oncology hospital in Poland

A new set‐up of vanishing antibodies: A biennial follow‐up of five different clients' humoral responses against SARS‐CoV‐2 after systemic vaccination in an oncology hospital in Poland

Bibliographic Details
Main Authors:	Piotr Kosiorek, Samuel Stróż, Anna Hryniewicz, Dorota E. Kazberuk, Robert Milewski, Klaudia Bartoszewicz, Magdalena J. Borkowska, Anna Stasiak‐Barmuta
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Series:	Health Science Reports
Subjects:	BNT162b2 COVID‐19 SARS‐CoV‐2 seroconversion S‐RBD vaccination
Online Access:	https://doi.org/10.1002/hsr2.1172

Similar Items

Systemic COVID-19 Vaccination Enhances the Humoral Immune Response after SARS-CoV-2 Infection: A Population Study from a Hospital in Poland Criteria for COVID-19 Reimmunization Are Needed
by: Piotr Kosiorek, et al.
Published: (2022-02-01)

SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia
by: Yared Merid, et al.
Published: (2023-06-01)

Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis
by: Miriam Hernández-Porto, et al.
Published: (2022-09-01)

A Longitudinal Study in Turkiye of Host Ability to Produce Antibodies following a Third Homologous BNT162b2 Vaccination
by: Mustafa Genco Erdem, et al.
Published: (2023-03-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)

Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study
by: Mustafa Genco Erdem, et al.
Published: (2023-03-01)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
by: Mina Psichogiou, et al.
Published: (2021-09-01)

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children
by: Marcello Mariani, et al.
Published: (2022-08-01)

Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study
by: Keita Yamashita, et al.
Published: (2022-06-01)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
by: Angelos Hatzakis, et al.
Published: (2022-02-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01)

Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine
by: Ahmet Can Topçu, et al.
Published: (2023-04-01)

Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia
by: Naif Khalaf Alharbi, et al.
Published: (2022-05-01)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
by: Chin Shern Lau, et al.
Published: (2022-11-01)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
by: Erez Bar-Haim, et al.
Published: (2022-05-01)

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study
by: Hakan Demirhindi, et al.
Published: (2022-04-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination
by: Giuseppina Sanna, et al.
Published: (2022-03-01)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
by: Areti Tychala, et al.
Published: (2021-12-01)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
by: Einat Shacham Shmueli, et al.
Published: (2022-08-01)

Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine
by: Luca Coppeta, et al.
Published: (2022-01-01)

Cervical and Axillary Lymphadenopathy After Administrating mRNA BNT-162b2 Vaccine Against COVID-19: Clinical and Sonographic Findings, Outcomes of Short-term Follow-up
by: Umur Anıl PEHLİVAN, et al.
Published: (2022-06-01)

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
by: Palittiya Sintusek, et al.
Published: (2022-08-01)

The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults
by: Paweł Matryba, et al.
Published: (2022-03-01)

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
by: Mandy Schwarze, et al.
Published: (2022-06-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
by: Itzchak Levy, et al.
Published: (2022-07-01)

Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
by: Jun Otani, et al.
Published: (2021-10-01)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
by: Mohammad Shehab, et al.
Published: (2021-11-01)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
by: Toshio Naito, et al.
Published: (2022-01-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Napaporn Chantasrisawad, et al.
Published: (2022-05-01)

Is a single COVID-19 vaccine dose enough in convalescents ?
by: Daniele Focosi, et al.
Published: (2021-09-01)

Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
by: Morales-Núñez JJ, et al.
Published: (2022-08-01)

Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
by: Matteo Nioi, et al.
Published: (2021-11-01)

Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance
by: Vanessa De Pace, et al.
Published: (2023-08-01)

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
by: Federico Gobbi, et al.
Published: (2021-03-01)

The Impact of Vaccination against SARS-CoV-2 on Health Outcomes and Hospital Visits after Omicron Infection in Children and Adolescents Aged 5–18 Years: A Danish Nation-Wide Cohort Study
by: Selina Kikkenborg Berg, et al.
Published: (2023-11-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Safety and Immunogenicity of a Single Dose of BNT162b2 COVID-19 mRNA Vaccine in a Warfarin-Treated Protein S Deficient Patient: A Case Report and Literature Review
by: Cucunawangsih Cucunawangsih, et al.
Published: (2022-12-01)